Kissei Pharmaceutical

Diversified pharma

4547 · TSE · Japan

Public Market Listing

4547TSE

TSE primary exchange listing

Live quotes, historical charts, and market capitalization for Kissei Pharmaceutical are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(7 total)
7Total Assets
3Approved
3Phase 3 / Filed
1Phase 1–2 / Early
7Diseases
Quick filter:
Showing 7 of 7 assets
Target & Modality
fostamatinib(Tavalisse)
Approved
Spleen tyrosine kinase (Syk)Small molecule
Immune Thrombocytopenia
Approved
Mutant IDH1Small molecule
Acute Myeloid LeukemiaGlioma
Relapsed/Refractory Acute Myeloid Leukemia
Approved
Dietary phosphateSmall molecule
Chronic Kidney DiseaseHyperphosphatemia
JR-131No recent activity
Phase 3
Erythropoietin receptor (EPO-R)Biologic (subtype unspecified)
Chronic Kidney Disease
Mitiglinide(Glufast)
Phase 3
SUR1 (short-acting)Small molecule
Type 2 Diabetes
Omarigliptin(Marizev)
Phase 3
DPP-4Small molecule
Indication not yet linked
Phase 2
D2/D3Small molecule
Parkinson's Disease

Discontinued programmes (1)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (1)
June 2029 (1)
OlutasidenibPhase 2High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV, Diffuse Intrinsic Pontine Glioma, WHO Grade III Glioma …
Est. primary completion 2029-06 · NCT06161974 · CT.gov ↗
What to watch
2030 (1)
September 2030 (1)
OlutasidenibPhase 2Relapsed or Refractory IDH1 Mutation-Positive Acute Myeloid Leukemia
Est. primary completion 2030-09 · NCT07604064 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Annual history (6 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
FY2026$595M—$330M—report ↗
View 5 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-FY$642M$148M$340M—report ↗
2025-FY$580M$85M$321M—report ↗
2024-FY$520M$65M$303M—report ↗
2023-FY$496M$76M$367M—report ↗
2022-FY$581M$92M$434M—report ↗